Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/
Employees: 11-50
Total raised: $167M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 02.10.2022 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.09.2022 | Series B | $132M | - |
| 22.07.2021 | Series A | $35M | - |
Mentions in press and media 4
| Date | Title | Description |
| 22.09.2022 | Rivus Pharmaceuticals Closes $132M Series B Financing | Rivus Pharmaceuticals Inc., a Charlottesville, VA-based clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, completed a $132m Series B financing. The round was led by RA Capital Management with participa... |
| 22.07.2021 | Rivus Pharmaceuticals Raises $35M in Series A Financing | Rivus Pharmaceuticals, Inc., a Charlottesville, Va.-based biopharmaceutical company dedicated to improving cardio-metabolic health, closed a $35m Series A financing. The round was co-led by Longitude Capital and Medicxi and RxCapital also p... |
| 20.07.2021 | Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases | |
| - | Rivus Pharmaceuticals | “Rivus will improve cardio-metabolic health with targeted metabolic accelerators (TMAs) to address the risk factors for cardiovascular mortality and morbidity.” |